Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNAi therapeutics.

Alnylam Pharmaceuticals Inc.

Market Data

S&P 500 Movers

CRL -2.8

Range dropdown markets

Oil 73.58 0.77 1.06

All Times Eastern Latest News

Scroll up, scroll down


Toggle chart options

Dropdown Range

$ % Vol

Volume: 1.3M 65-Day Average: 777.33K

168% vs. Avg 187.94 Days Range 194.25, 117.58 52-Week Range 242.97

Partner Center

Your Watchlists

Recent Viewed Tickers

Key Data

Float Shorted at 4.00%
Average Volume 777.33K


5 Days


1 Month


3 Months




1 Year


Analyst Ratings


Number of Ratings 26 Ratings Full

MarketWatch Dow Jones

Alnylam Pharma Chairman Stepping Down

Jan. 5, 2023, at 4:44 p.m. ET

Biotech and Pharma Karuna's Schizophrenia Trial Data Are the 'Best Case Scenario’ for the Biotech Stock

August 8, 2022, 11:48 a.m. ET by Barron's

Biotech and Pharma: The bull market in biotech stocks is still going strong

Aug. 4, 2022, 9:41 AM ET by Barron's

Biotech and Pharma Alnylam Stock Rockets Half-Off Trial Results Give Hope for a Blockbuster

Aug. 3, 2022, 11:21 a.m. ET by Barron's

Stock of Alnylam jumps 57% after it shares positive news about its experimental RNAi treatment

Aug. 3, 2022, 8:17 a.m. ET by Jaimy Le

Biotech and Pharma add to litigation concerns for moderna stock

Mar. 18, 2022, 10:16 a.m. ET by Barron's

Alnylam Pharmaceuticals outperforms Oppenheimer

Nov. 1, 2021, 7:42 a.m. ET by Tomi Kilgore

Alnylam Pharmaceuticals upgrades to buy from UBS

Oct. 4, 2021, 9:39 a.m. ET by Tomi Kilgore

Biotech and Pharma Intellia Stocks Are Exploding Due to a Gene Editing Breakthrough

28th of June 2021, 10:39 a.m. ET by Barron's

Intellia is a good place to look for biotech and pharmaceutical gene editing data. This is how it made history.

28th of June 2021, 8:39 a.m. ET by Barron's

Biotech and Pharma Vir will Test Its Covid-19Antibody with Eli Lilly's, Recommending Shares

Jan. 27, 2021, 10:08 a.m. ET by Barron's

Alnylam Pharmaceuticals is downgraded at BMO Capital to market perform, from outperform

Jan. 25, 2021, 9:20 a.m. ET by Tomi Kilgore

Options: Get ready for the wild world of health-care stocks. How to Play Them.

Jan. 5, 2021, 6:00 a.m. ET by Barron's

Real Estate Blackstone's Deal for Lab Space of $3.45 billion Shows Boom in Life Sciences

Dec. 14, 2020, 3:51 p.m. ET by Barron's

Oppenheimer downgrades Alnylam Pharmaceuticals to outperform

August 11, 2020 at 7:54 AM ET by Tomi Kilgore

Health Drops Out as a Top Contestant in the Race to Obtain a NASH Drug

23.02.2020 at 11:02 a.m. ET by Barron's

Alnylam Pharmaceuticals' stock price target increased to $196, from $173 at BMO Kapital

20 at 8:38 AM, 2020 ET by Tomi Kilgore

J.P. Morgan downgrades Alnylam Pharmaceuticals to neutral from overweight

7, 2020 at 8:13 am. ET by Tomi Kilgore

These 23 companies are currently working on vaccines or treatments for coronavirus. Here's what we know.

6:50 p.m. ET by Jaimy Le

Other News Press Releases

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals, Inc., a global, commercial-stage biopharmaceutical firm, engages in the development, commercialization, and discovery of RNAi therapeutics. ONPATTRO and GIVLAARI are its products. Phillip A., Phillip A., Thomas Tuschl and Phillip Zamore founded the company. Sharp was founded by Phillip A. Sharp on June 14, 2002. It is headquartered at Cambridge, MA.


Arrowhead Pharmaceuticals Corp. –0.53% $2.65B